Please ensure Javascript is enabled for purposes of website accessibility

AbbVie Reports Successful Trial Results for Arthritis Drug

By Jim Crumly – Feb 5, 2020 at 4:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A future blockbuster scores another success as AbbVie works to replace Humira losses.

AbbVie (ABBV 1.50%) reported that its new immunology drug Rinvoq (upadacitinib) successfully met primary and secondary endpoints in a registrational trial for treatment of psoriatic arthritis, clearing the way for the company to file a new drug application (NDA) for the indication later this year.

In the study of 1,705 adults who had previously been treated unsuccessfully with non-biologic arthritis drugs, 79% of the group taking the highest of two tested doses of Rinvoq had at least a 20% improvement in disease symptoms after 12 weeks compared with 36% of the placebo group. After 16 weeks, 62% of the group achieved a 75% improvement in skin symptoms, compared with 21% of the patients on a placebo. And at the 24-week mark, 45% of the high-dose group achieved minimal disease activity, the goal in treating arthritis, versus 12% in the placebo group.

Elderly woman rubbing arthritic hand.

Image source: Getty Images.

The trial also compared Rinvoq to AbbVie's Humira, the world's top-selling drug that's under threat from biosimilars, and those results may not be as conclusive as the company was hoping. Rinvoq was superior to Humira in producing a 20% symptom improvement after 12 weeks only at the higher dose and was shown only to be non-inferior at the lower dose. The company didn't release comparative results for Humira on the other efficacy measures.

The study confirmed results from an earlier, smaller study that read out in October, and AbbVie said in the last conference call that positive results from this trial would lead to regulatory submission in mid-2020 and commercialization in 2021. Rinvoq is already approved in the U.S. for rheumatoid arthritis and the company has the drug in trials for six other diseases.

AbbVie will report fourth-quarter earnings on Friday, Feb. 7.

Jim Crumly owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$143.85 (1.50%) $2.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.